The association between soy isoflavone intake and menopausal symptoms after breast cancer diagnosis: a prospective longitudinal cohort study on Chinese breast cancer patients
Publication in refereed journal


引用次數
Scopus ( 19/11/2020)
替代計量分析
.

其它資訊
摘要Purpose
This study investigated the association between soy isoflavone intake and menopausal symptoms (MPS) among
Chinese women with early stage breast cancer in a prospective cohort study.

Methods
In an on-going prospective cohort study that involved 1462 Chinese women with early stage breast cancer, MPS
were assessed at 18, 36 and 60 months after cancer diagnosis using the validated menopausal rating scale (MRS) questionnaire. Daily soy food intake for the previous 12 months was assessed at the same time using a validated food frequency questionnaire. The associations between MPS and soy isoflavone intake were evaluated in multivariable logistic regression analyses.

Results
The prevalence of MPS was almost the same during the first 60 months after cancer diagnosis, which were 64.5%,
65.2%, and 63.9% at 18, 36, and 60 months, respectively. Patients with MPS tended to be younger than those without MPS. The intake of soy isoflavones was not associated with the total score of MRS at 18-month follow-up [highest vs lowest tertile, odds ratio (OR) = 1.00, 95% CI 0.75–1.34]. Similarly, no significant association was noted at 36-month (OR = 1.25, 95% CI 0.92–1.69) and 60-month (OR = 1.21, 95% CI 0.84–1.74) follow-up. With regards to specific domain within MRS, the risk of symptoms presenting in somatic domain was higher among breast cancer patients who were in the highest tertile of soy isoflavone intake at 36 months post-diagnosis (OR = 1.44, 95% CI 1.07–1.94, P-trend = 0.02), compared with the lowest tertile, where a stronger significant association was noted among patients who were younger than 60 years (OR = 1.52, 95% CI 1.05–2.20, P-trend = 0.03) and pre-menopausal (OR = 3.81, 95% CI 1.85–8.11, P-trend < 0.01).

Conclusion
The present study provided further evidence that soy isoflavone consumption was not associated with MPS
among Chinese breast cancer patients. In fact, patients with higher intake of soy isoflavone have increased risk of experiencing somatic symptoms.
出版社接受日期24.03.2020
著者Lei YY, Ho SC, Cheng A, Kwok C, Cheung KL, He YQ, Lee R, Yeo W
期刊名稱Breast Cancer Research and Treatment
出版年份2020
月份5
卷號181
期次1
出版社Springer
頁次167 - 180
國際標準期刊號0167-6806
電子國際標準期刊號1573-7217
語言英式英語
關鍵詞Breast cancer, Soy isoflavone intake, Menopausal symptoms, Chinese women

上次更新時間 2020-19-11 於 23:59